Project Grant R21AI202371
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $490K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, ME 04102, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Oregon Health & Science University $442,758 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify drug targets in Mycobacterium abscessus through fluorescent probe application. Performance runs through January 31, 2028, in Portland, Oregon. M. abscessus causes the most difficult-to-treat and highest-mortality non-tuberculous mycobacterial pulmonary infections in the United...
- The National Institute of Allergy and Infectious Diseases awarded $440,908 to the University of Illinois on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop extracellular vesicle-inspired nano vesicles for CRISPR-based targeting of methicillin-resistant Staphylococcus aureus (MRSA). The project addresses antibiotic resistance in MRSA strains, the leading cause of healthcare-associated infections in the United States and globally. Current...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $3,064,333 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research investigating how the host immune response influences methicillin-resistant Staphylococcus aureus susceptibility to antibiotics in skin and soft tissue infections. The research comprises three specific aims. Aim 1 examines how neutrophils enriched during the...
- The National Institute of Allergy and Infectious Diseases awarded $130,199 to the University of California, San Diego on December 23, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate macrophage membrane-coated nanoparticles (MF-NPs) as adjuvant therapy for severe bacterial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA). The research comprises two aims: testing in vitro whether MF-NPs modulate neutrophil responses to MRSA and...
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital $800,557 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how the pathogen Staphylococcus aureus manipulates inflammasome activities critical to host defense. The funded research identifies mechanisms by which diverse S. aureus strains, including toxigenic and non-toxigenic variants, activate inflammasome regulatory proteins in immune cells....
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $186,758 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on infection-induced cell cycle diversion and macrophage inflammatory biogenesis. The award funds investigation into how bacterial infection of macrophages, specifically by methicillin-resistant Staphylococcus aureus (MRSA), triggers structural and biochemical...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $233,250 for Project Grant R21AI201981 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into cethromycin-based treatment regimens for Mycobacterium avium disease. The study will evaluate whether cethromycin, a next-generation macrolide (ketolide), offers superior efficacy over current standard-of-care multidrug therapies. M. avium is...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded Indiana University Indianapolis $673,584 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize methicillin-resistant Staphylococcus aureus (MRSA) infection dynamics in renal tissue and identify therapeutic strategies to disrupt kidney colonization during bloodstream infection. The...
- The National Institute of Allergy and Infectious Diseases awarded $533,850 to the University of Texas at Arlington on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into the pathogenesis of Staphylococcus aureus thymidine-dependent small-colony variants in cystic fibrosis patients. The research characterizes how thymidine-dependent small-colony variants, which frequently colonize CF airways following anti-folate antibiotic exposure,...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $599,327 to Microbiotix, Inc. on September 22, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel benzyl-piperidine antifungal agents targeting intractable mucormycosis infections caused by drug-resistant Mucorales fungi. The project focuses on chemical optimization of a benzyl-piperidine series to improve drug-like properties and...